Evidence map›Paper›PMID 26858653›Full record

ArticleFrontiers in physiology2016

Na,K-ATPase Isozymes in Colorectal Cancer and Liver Metastases.

Marc Baker Bechmann, Deborah Rotoli, Manuel Morales, María Del Carmen Maeso, María Del Pino García, Julio Ávila, Ali Mobasheri, Pablo Martín-Vasallo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Displacement of Native FXYD Protein From NaFrontiers in oncology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Marc Baker BechmannLaboratorio de Biología del Desarrollo, UD de Bioquímica y Biología Molecular and Centro de Investigaciones Biomédicas de Canarias, Universidad de La Laguna Santa Cruz de Tenerife, Spain.
Deborah RotoliLaboratorio de Biología del Desarrollo, UD de Bioquímica y Biología Molecular and Centro de Investigaciones Biomédicas de Canarias, Universidad de La LagunaSanta Cruz de Tenerife, Spain; Institute of Endocrinology and Experimental Oncology, National Research CouncilNaples, Italy.
Manuel MoralesService of Medical Oncology, University Hospital Nuestra Señora de CandelariaSanta Cruz de Tenerife, Spain; Medical Oncology, Hospiten HospitalsSanta Cruz de Tenerife, Spain.
María Del Carmen MaesoService of Pathology, University Hospital Nuestra Señora de Candelaria Santa Cruz de Tenerife, Spain.
María Del Pino GarcíaDepartment of Pathology, Hospiten Hospitals Santa Cruz de Tenerife, Spain.
Julio ÁvilaLaboratorio de Biología del Desarrollo, UD de Bioquímica y Biología Molecular and Centro de Investigaciones Biomédicas de Canarias, Universidad de La Laguna Santa Cruz de Tenerife, Spain.
Ali MobasheriDepartment of Veterinary Preclinical Sciences, Faculty of Health and Medical Sciences, University of SurreyGuildford, UK; Faculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Fahd Medical Research Center, King AbdulAziz UniversityJeddah, Saudi Arabia.
Pablo Martín-VasalloLaboratorio de Biología del Desarrollo, UD de Bioquímica y Biología Molecular and Centro de Investigaciones Biomédicas de Canarias, Universidad de La Laguna Santa Cruz de Tenerife, Spain.
Universidad de La Laguna · ESHospital Universitario Nuestra Señora de Candelaria · ESHospiten Group · ESInstitute for Experimental Endocrinology and Oncology · ITKing Abdulaziz University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this study was to define Na,K-ATPase α and β subunit isoform expression and isozyme composition in colorectal cancer cells and liver metastases. The α1, α3, and β1 isoforms were the most highly expressed in tumor cells and metastases; in the plasma membrane of non-neoplastic cells and mainly in a cytoplasmic location in tumor cells. α1β1 and α3β1 isozymes found in tumor and metastatic cells exhibit the highest and lowest Na(+) affinity respectively and the highest K(+) affinity. Mesenchymal cell isozymes possess an intermediate Na(+) affinity and a low K(+) affinity. In cancer, these ions are likely to favor optimal conditions for the function of nuclear enzymes involved in mitosis, especially a high intra-nuclear K(+) concentration. A major and striking finding of this study was that in liver, metastasized CRC cells express the α3β1 isozyme. Thus, the α3β1 isozyme could potentially serve as a novel exploratory biomarker of CRC metastatic cells in liver.

Indexed as

colorectal cancercolorectal cancer liver metastasesNa/K-ATPase isoforms colorectal cancer immunohistochemistryNa/K-ATPase isozymessodium pump isozymes

Identifiers

PMID26858653
PMCPMC4731494
OpenAlexW2283520462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.